![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Schoser, Benedikt 
ORCID: https://orcid.org/0000-0002-2757-8131; Kishnani, Priya S.; Bratkovic, Drago; Byrne, Barry J.; Claeys, Kristl G.; Díaz-Manera, Jordi; Laforêt, Pascal; Roberts, Mark; Toscano, Antonio; Ploeg, Ans T. van der; Castelli, Jeff; Goldman, Mitchell; Holdbrook, Fred; Sitaraman Das, Sheela; Wasfi, Yasmine und Mozaffar, Tahseen
(28. Februar 2024):
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
In: Journal of Neurology, Bd. 271, Nr. 5: S. 2810-2823
[PDF, 944kB]
ORCID: https://orcid.org/0000-0002-2757-8131; Kishnani, Priya S.; Bratkovic, Drago; Byrne, Barry J.; Claeys, Kristl G.; Díaz-Manera, Jordi; Laforêt, Pascal; Roberts, Mark; Toscano, Antonio; Ploeg, Ans T. van der; Castelli, Jeff; Goldman, Mitchell; Holdbrook, Fred; Sitaraman Das, Sheela; Wasfi, Yasmine und Mozaffar, Tahseen
(28. Februar 2024):
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
In: Journal of Neurology, Bd. 271, Nr. 5: S. 2810-2823
[PDF, 944kB]
Vender, Ron; Gordon, Kenneth B.; Duffin, Kristina Callis; Bissonnette, Robert; Prinz, Jörg C.; Han, Chenglong; Wasfi, Yasmine; Shen, Yaung-Kaung; Randazzo, Bruce und Reich, Kristian
(2016):
Comparison of guselkumab with placebo and adalimumab on health-related quality of life in a phase 2b clinical trial X-PLORE.
In: Journal of the American Academy of Dermatology, Bd. 74, Nr. 5:
AB241-AB241